Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDF NASDAQ:HURA OTCMKTS:PVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$2.10+1.0%$3.10$2.06▼$5.64$139.70M1.291.27 million shs862,176 shsHURATuHURA Biosciences$2.70-3.9%$2.65$1.80▼$8.40$135.13M-0.1801,808 shs220,226 shsPVCTProvectus Biopharmaceuticals$0.08-1.0%$0.08$0.07▼$0.15$33.79M0.53127,550 shs28,491 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology0.00%-9.48%-20.45%-37.31%-9.09%HURATuHURA Biosciences0.00%-16.92%+12.50%-13.46%+269,999,900.00%PVCTProvectus Biopharmaceuticals0.00%+0.63%-12.51%+0.63%-10.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDFCardiff Oncology2.0612 of 5 stars3.41.00.00.02.71.70.6HURATuHURA Biosciences1.4897 of 5 stars3.70.00.00.02.40.00.0PVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDFCardiff Oncology 2.83Moderate Buy$10.10380.95% UpsideHURATuHURA Biosciences 3.40Buy$12.67369.14% UpsidePVCTProvectus Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PVCT, PTNT, HURA, and CRDF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $10.007/8/2025CRDFCardiff OncologyLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$3.506/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDFCardiff Oncology$545K256.34N/AN/A$1.86 per share1.13HURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/APVCTProvectus Biopharmaceuticals$620K54.50N/AN/A($0.01) per share-8.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)HURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A-248.79%-150.83%10/6/2025 (Estimated)PVCTProvectus Biopharmaceuticals-$4.76MN/A0.00∞N/A-1,374.19%N/A-792.87%11/10/2025 (Estimated)Latest PVCT, PTNT, HURA, and CRDF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HURATuHURA Biosciences-$0.14-$0.21-$0.07-$0.21N/AN/A7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDFCardiff OncologyN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDFCardiff OncologyN/A4.424.42HURATuHURA BiosciencesN/A0.830.83PVCTProvectus BiopharmaceuticalsN/A0.090.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDFCardiff Oncology16.29%HURATuHURA Biosciences0.62%PVCTProvectus Biopharmaceuticals0.05%Insider OwnershipCompanyInsider OwnershipCRDFCardiff Oncology7.70%HURATuHURA Biosciences0.20%PVCTProvectus Biopharmaceuticals14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableHURATuHURA BiosciencesN/A50.05 million49.95 millionN/APVCTProvectus Biopharmaceuticals4420.28 million366.48 millionNot OptionablePVCT, PTNT, HURA, and CRDF HeadlinesRecent News About These CompaniesProvectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - MorningstarJune 27, 2025 | morningstar.comMProvectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck CancerJune 26, 2025 | globenewswire.comProvectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of StockholdersJune 9, 2025 | globenewswire.comCroatia's Provectus Capital Partners opens office in RomaniaApril 24, 2025 | seenews.comSProvectus announces $3M seed financing round for VisiRoseJanuary 14, 2025 | markets.businessinsider.comProvectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye DrugsJanuary 14, 2025 | markets.businessinsider.comProvectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye DrugsJanuary 14, 2025 | globenewswire.comProvectus launches VisiRose, Provectus’s Founded Entity for pharmaceutical-grade rose bengal sodium-based treatments in ophthalmologyDecember 13, 2024 | pharmabiz.comPProvectus announces the launch of VisiRoseDecember 12, 2024 | markets.businessinsider.comVisiRose Introduces Revolutionary Therapy for Severe Eye InfectionsDecember 10, 2024 | miamiherald.comMProvectus Pharmaceuticals Aligns Leadership with Equity GrantsDecember 6, 2024 | markets.businessinsider.comProvectus Pharmaceuticals to Reveal Key 2024 UpdatesNovember 15, 2024 | markets.businessinsider.comProvectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comProvectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference CallOctober 24, 2024 | manilatimes.netMProvectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference CallOctober 10, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual MeetingMay 21, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual MeetingMay 14, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor CancersApril 18, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value CreationApril 16, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal SodiumMarch 27, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePVCT, PTNT, HURA, and CRDF Company DescriptionsCardiff Oncology NASDAQ:CRDF$2.10 +0.02 (+0.96%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.12 +0.02 (+0.71%) As of 08/29/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.TuHURA Biosciences NASDAQ:HURA$2.70 -0.11 (-3.91%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.72 +0.02 (+0.74%) As of 08/29/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Provectus Biopharmaceuticals OTCMKTS:PVCT$0.08 0.00 (-0.99%) As of 08/29/2025 02:46 PM EasternProvectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
